- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Andre Goy Discusses What We’ve Learned About CAR T Therapies and Cytokine Responses
Andre Goy, MD, of John Theurer Cancer Center, discussed what we’ve learned from existing chimeric antigen receptor T (CAR T)-cell therapies in managing cytokine responses.
Andre Goy, MD, chairman, director, and chief of the Division of Lymphoma at John Theurer Cancer Center in Hackensack, NJ, discussed what we’ve learned from existing chimeric antigen receptor T (CAR T)-cell therapies in managing cytokine responses.
Transcript
Since the approval of the first two CAR T-cell therapies, and their use outside the clinical trial setting, what are the most important things we have learned about the management of cytokine release syndrome [CRS]?
We have made a lot of progress in managing patient with CAR T-cells in terms of toxicity, particularly with their cytokine release syndrome and with the use of anti-IL-6 receptor with tocilizumab or infliximab. We use it prophylactically, preemptively and this has been very helpful in mitigating some of the CRS aspect. We also have used steroids and there's been some studies looking at preemptive use of steroids [garbled] in a context of CAR-T to improve the toxicity profile. And what has been interesting is that not only has the toxicity profile improved, but it has not really affected the responses and the outcome.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
